NeoGenomics, Inc. Repayments of Secured Debt
NeoGenomics, Inc. (NEO) reported Repayments of Secured Debt of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-24.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfSecuredDebt · last filed 2023-02-24
- NeoGenomics, Inc. repayments of secured debt for the quarter ending 2021-12-31 was $0.00.
- NeoGenomics, Inc. repayments of secured debt for the quarter ending 2021-09-30 was $0.00.
- NeoGenomics, Inc. repayments of secured debt for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- NeoGenomics, Inc. repayments of secured debt for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- NeoGenomics, Inc. repayments of secured debt for fiscal 2022 was $0.00.
- NeoGenomics, Inc. repayments of secured debt for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- NeoGenomics, Inc. repayments of secured debt for fiscal 2020 was $97.54M, a 1.72% decline from fiscal 2019.
- NeoGenomics, Inc. repayments of secured debt for fiscal 2019 was $99.25M, a 2105.56% increase from fiscal 2018.
| Period end | Repayments of Secured Debt 3 month | Repayments of Secured Debt 6 month | Repayments of Secured Debt 9 month | Repayments of Secured Debt 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-24 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $0.00 derived: sum of 2 quarters · filed 2023-02-24 | $0.00 derived: sum of 3 quarters · filed 2023-02-24 | $0.00 10-K · filed 2023-02-24 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $0.00 10-Q · filed 2021-08-09 | $0.00 derived: sum of 3 quarters · filed 2023-02-24 | $0.00 derived: sum of 4 quarters · filed 2023-02-24 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-06 | $0.00 derived: sum of 2 quarters · filed 2023-02-24 | $0.00 derived: sum of 3 quarters · filed 2023-02-24 | $96.29M derived: sum of 4 quarters · filed 2023-02-24 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $0.00 derived: sum of 2 quarters · filed 2023-02-24 | $96.29M derived: sum of 3 quarters · filed 2023-02-24 | $97.54M 10-K · filed 2023-02-24 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $96.29M derived: sum of 2 quarters · filed 2021-11-04 | $97.54M 10-Q · filed 2021-11-04 | $100.04M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $96.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $97.54M 10-Q · filed 2021-08-09 | $100.04M derived: sum of 3 quarters · filed 2022-02-25 | $100.04M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $1.25M 10-Q · filed 2021-05-06 | $3.75M derived: sum of 2 quarters · filed 2022-02-25 | $3.75M derived: sum of 3 quarters · filed 2022-02-25 | $98.53M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $2.50M derived: sum of 2 quarters · filed 2022-02-25 | $97.28M derived: sum of 3 quarters · filed 2022-02-25 | $99.25M 10-K · filed 2022-02-25 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $94.78M derived: sum of 2 quarters · filed 2020-10-29 | $96.75M 10-Q · filed 2020-10-29 | $98.06M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $94.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $96.75M 10-Q · filed 2020-07-31 | $98.06M derived: sum of 3 quarters · filed 2021-02-25 | $93.97M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $1.97M 10-Q · filed 2020-04-29 | $3.28M derived: sum of 2 quarters · filed 2021-02-25 | -$807.00K derived: sum of 3 quarters · filed 2021-02-25 | $130.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$2.77M derived: sum of 2 quarters · filed 2021-02-25 | -$1.84M derived: sum of 3 quarters · filed 2021-02-25 | $4.50M 10-K · filed 2021-02-25 |
| 2018-09-30 | -$4.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | -$3.15M derived: sum of 2 quarters · filed 2019-11-13 | $3.19M 10-Q · filed 2019-11-13 | $4.12M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | $937.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $7.28M 10-Q · filed 2019-08-07 | $8.21M derived: sum of 3 quarters · filed 2020-02-28 | |
| 2018-03-31 | $6.34M 10-Q · filed 2019-05-08 | $7.28M derived: sum of 2 quarters · filed 2020-02-28 | ||
| 2017-12-31 | $937.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $3.75M 10-K · filed 2020-02-28 | ||
| 2017-09-30 | $2.82M 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |